fda glp 1 shortage list Proposes Ban on Bulk Compounding for Semaglutide, Tirzepatide, and Liraglutide GLP-1 Shortage = Over -
Description
A study of almost 2000 people published in February 2021 has shown that a new, once-a-week weight loss injection can help patients with obesity.
Medical disclaimer: This article is for informational purposes only and is not medical advice
Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.
The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs
